SpringWorks Therapeutics Inc (SWTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SpringWorks Therapeutics Inc (SWTX) has a cash flow conversion efficiency ratio of -0.165x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-68.76 Million) by net assets ($417.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see SpringWorks Therapeutics Inc (SWTX) market capitalisation for the company's overall valuation and market capitalisation.
SpringWorks Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2000–2024)
This chart illustrates how SpringWorks Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
SpringWorks Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SpringWorks Therapeutics Inc ranked by their cash flow conversion efficiency. Explore SpringWorks Therapeutics Inc cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ZIM Integrated Shipping Services Ltd
NYSE:ZIM
|
0.102x |
|
Poco Holding Co Ltd
SHE:300811
|
0.018x |
|
Bright Horizons Family Solutions Inc
NYSE:BFAM
|
0.101x |
|
Shenzhen Goodix Technology Co Ltd Class A
SHG:603160
|
0.039x |
|
Xiamen C&D Inc
SHG:600153
|
-0.060x |
|
Shaanxi Sirui Advanced Materials Co. Ltd. A
SHG:688102
|
N/A |
|
Kinetik Holdings Inc
NYSE:KNTK
|
0.063x |
|
Choice Properties Real Estate Investment Trust
TO:CHP-UN
|
0.012x |
Annual Cash Flow Conversion Efficiency for SpringWorks Therapeutics Inc (2000–2024)
The table below shows the annual cash flow conversion efficiency of SpringWorks Therapeutics Inc from 2000 to 2024. View SpringWorks Therapeutics Inc (SWTX) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $481.10 Million | $-175.60 Million | -0.365x | -2.59% |
| 2023-12-31 | $626.22 Million | $-222.79 Million | -0.356x | -22.92% |
| 2022-12-31 | $558.19 Million | $-161.56 Million | -0.289x | +4.39% |
| 2021-12-31 | $422.40 Million | $-127.88 Million | -0.303x | -423.89% |
| 2020-12-31 | $557.06 Million | $-32.19 Million | -0.058x | +60.77% |
| 2019-12-31 | $322.07 Million | $-47.44 Million | -0.147x | -119.40% |
| 2018-12-31 | $-19.37 Million | $-14.71 Million | 0.759x | -10.99% |
| 2017-12-31 | $-2.62 Million | $-2.24 Million | 0.853x | +460.05% |
| 2010-12-31 | $36.81 Million | $5.61 Million | 0.152x | -20.90% |
| 2009-12-31 | $27.15 Million | $5.23 Million | 0.193x | -41.95% |
| 2008-12-31 | $21.41 Million | $7.10 Million | 0.332x | -2.79% |
| 2007-12-31 | $16.69 Million | $5.70 Million | 0.341x | +440.29% |
| 2006-12-31 | $11.85 Million | $748.00K | 0.063x | -74.88% |
| 2005-12-31 | $15.94 Million | $4.01 Million | 0.251x | -4.37% |
| 2004-12-31 | $14.57 Million | $3.83 Million | 0.263x | -49.59% |
| 2001-12-31 | $26.45 Million | $13.79 Million | 0.521x | +561.99% |
| 2000-12-31 | $20.14 Million | $1.59 Million | 0.079x | -- |
About SpringWorks Therapeutics Inc
SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. It offers OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor for the treatment of desmoid tumors; and GOMEKLI (mirdametinib), an oral small molecule inhibitor o… Read more